Needham & Co. Reiterates 'Buy' Rating On Cara, Sees 65% Upside

Yesterday, Needham & Co.'s Alan Carr reiterated a 'buy' rating on shares of Cara Therapeutics, Inc.

Yesterday, Needham & Co.'s Alan Carr reiterated a 'buy' rating on shares of Cara Therapeutics, Inc.

Read the full article on The Daily Marijuana Observer!

Subscribe to our Cannabinoid Biotech Updates

Other Recent CARA News:

Jim Cramer Interviews CARA CEO on Mad Money

Disclaimer: This and other personal blog posts are not reviewed, monitored or endorsed by TalkMarkets. The content is solely the view of the author and TalkMarkets is not responsible for the content of this post in any way. Our curated content which is handpicked by our editorial team may be viewed here.

STOCKS IN THIS BLOG POST

Comments